Ambien hit with reports of sleep-eating

M. I.
April 2006
Medical Marketing & Media;Apr2006, Vol. 41 Issue 4, p11
Trade Publication
The article examines reports that link Sanofi-Aventis SA' Ambien (zolpidem) with episodes of sleepwalking and other side effects arising out of sleep in the United States. The reports discuss cases of Ambien patients bingeing on food and driving while in a semi-sleep state. In response, Sanofi-Aventis issued a statement noting that the drug is safe when taken as prescribed.


Related Articles

  • Ambien CR.  // Formulary;Oct2005, Vol. 40 Issue 10, p322 

    Reports on the U.S. Food and Drug Administration's approval for the new drug formulation Ambien CR, which are zolpidem extended-release tablets from Sanofi-Aventis. For improving sleep onset ad maintenance; Efficacy; Safety; Dosing.

  • Zolpidem.  // Reactions Weekly;9/16/2006, Issue 1119, p22 

    The article discusses research being done on zolpidem. It references a study by K. M. Malloy et al published in the June 2006 issue of "Sleep." A 55-year old woman has developed chronic rhinosinusitis while undergoing zolpidem for insomnia. Several symptoms were experienced by the patient...

  • PR View. Herskovits, Beth // Medical Marketing & Media;May2006, Vol. 41 Issue 5, p32 

    The author comments on the side effects associated with Sanofi-Aventis' sleeping pill, Ambien and the media coverage surrounding the issue. According to the author, the company has issued a statement emphasizing that the drug is safe and does not need a stronger warning label. The author claims...

  • Extended-release Ambien gains FDA nod.  // Drug Topics;9/26/2005, Vol. 149 Issue 18, p10 

    This article reports that Sanofi-Aventis SA has received U.S. Food and Drug Administration approval for its extended-release version of Ambien, or zolpidem tartrate, for the treatment of insomnia.

  • Zolpidem.  // Reactions Weekly;8/29/2009, Issue 1267, p31 

    The article describes the case of an adult woman who developed amnesia after receiving zolpidem. The patient experienced a total absence of recall of a long discussion with her boyfriend. Testing conducted during an ambulatory psychiatric session confirmed her amnesia. The discussion occurred...

  • SECTION 3: CENTRAL NERVOUS SYSTEM.  // MPR - Obstetrician & Gynecologist Edition;Fall/Winter2011, Vol. 22 Issue 2, p28 

    The article offers brief information on several medications for diseases in the central nervous system including Ambien, Estazolam, and Anafranil. Ambien, formulated from imidazopyridine and zolpidem tartrate by Sanofi-Aventis SA is indicated for insomnia. Estazolam, containing benzodiazepine,...

  • Zolpidem withdrawal delirium. Mattoo, Surendra K.; Gaur, Navendu; Das, Partha P. // Indian Journal of Pharmacology;Dec2011, Vol. 43 Issue 6, p729 

    The Z-category hypnotics are promoted for their relative safety. However, this view is challenged by the emerging clinical evidence in the form of zolpidem related intoxication delirium and seizures, and dependence and complicated withdrawal. We report the case of a zolpidem-naive...

  • Brotizolam/triazolam/zolpidem.  // Reactions Weekly;7/11/2009, Issue 1260, p9 

    The article describes the cases of a 14-year-old girl who received trizolam followed by brotizolam, and a 14-year-old girl who received zolpidem, who developed paradoxical reactions manifesting as anxiety, psychomotor agitation and confusion. The patients developed abnormal behaviors like...

  • CDC highlights unsafe use of zolpidem (Ambien) in USA.  // Reactions Weekly;May2015, Vol. 1553 Issue 1, p2 

    The article focuses on a report about the unsafe use of the sleep medication zolpidem in the U.S.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics